Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development ...

French inflammatory diseases specialist Abivax yesterday announced the closing of its previously announced underwritten ...

France-based life sciences venture capital firm Sofinnova today announced that its portfolio company Myricx Bio has reached ...

Sandoz (SDZ: SIX) has launched a direct-to-consumer platform in the USA, taking an unusual step for a global generics and biosimilars manufacturer by allowing self-pay patients to purchase medicines ...

The US Food and Drug Administration (FDA) has issued a warning letter to Genzyme Ireland, a Sanofi (Euronext: SAN) subsidiary, citing significant manufacturing violations at its Waterford biologics ...

Regulators in the USA, Japan, the UK, Switzerland, Australia and several other major international markets have issued a mix of safety statements, review updates, guidance changes, compliance notices ...

A biotech company developing first-in-class therapeutics for a wide range of difficult-to-treat diseases, including autoimmune and inflammatory diseases. Headquartered in South San Francisco, Lycia ...

A clinical-stage biopharmaceutical company pioneering immunometabolism-based therapies to treat chronic autoimmune and inflammatory diseases through oral small molecules that modulate immune cell ...

In last week’s news, US biotech Replimune’s resubmitted biologicals license application (BLA) for RP1 (vusolimogene oderparepvec) was accepted by the Food and Drug Administration. On the M&A front, ...

A Hong Kong–listed biotechnology company focused on the discovery, development and commercialization of small-molecule and peptide therapeutics. Ascletis Pharma develops medicines across metabolic ...

A Cambridge, UK-based clinical-stage biotech pioneering a proprietary class of bicyclic peptide (Bicycle) medicines targeting oncology and other high-unmet-need diseases underserved by conventional ...

India’s Orchid Pharma is in advanced negotiations to out-license its breakthrough antibiotic enmetazobactam in the USA, a move that could mark the company’s commercial entry into the world’s largest ...